Heron Therapeutics Company Profile (NASDAQ:HRTX)

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Wednesday, August, 9th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million for the quarter, compared to the consensus estimate of $4.53 million. View Heron Therapeutics' Earnings History.

9 analysts have issued 1-year price targets for Heron Therapeutics' stock. Their predictions range from $21.00 to $41.00. On average, they expect Heron Therapeutics' stock price to reach $31.43 in the next year. View Analyst Ratings for Heron Therapeutics.

Here are some recent quotes from research analysts about Heron Therapeutics stock:

• 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (7/12/2017)
• 2. Cowen and Company analysts commented, "Earlier today Heron stock dropped as much as 8.5% on seemingly no news." (5/26/2017)
• 3. Cantor Fitzgerald analysts commented, "Expensive 1Q: HRTX reported 1Q17 EPS of ($1.00), below our estimated ($0.83). The difference is mainly attributed to higher than expected R&D spend, though we believe that should taper off through the year, providing some flexibility in cash runway. HRTX finished the quarter with $165M in cash." (5/11/2017)
• 4. Needham & Company LLC analysts commented, "We initiate coverage of Heron Therapeutics, a commercial-stage specialty biopharma focused on novel extended-release injectables, at Buy with a $28 PT. HRTX made the transition to a commercial co. in 4Q16 with the launch of Sustol for CINV. Cinvanti, on file with FDA (likely 4Q17 PDUFA), will round out the CINV franchise. The main value driver, HTX-011, is an extended-release combination of bupivacaine/meloxicam in development for post-op pain management. HTX-011 successfully completed a comprehensive ph 2 program in various surgical procedures demonstrating superior efficacy to placebo and bupivacaine. HTX-011 will begin ph 3 development in 2017. Our valuation looks at the differentiated CINV assets and cash balance (~$215MM) as a floor value for HRTX, while the potential of HTX-011 remains mostly undervalued." (2/27/2017)

Heron Therapeutics saw a drop in short interest during the month of August. As of August 15th, there was short interest totalling 12,723,565 shares, a drop of 8.6% from the July 31st total of 13,920,842 shares. Based on an average daily trading volume, of 505,331 shares, the short-interest ratio is currently 25.2 days. Currently, 23.9% of the company's shares are sold short.

Some companies that are related to Heron Therapeutics include Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Immunomedics (IMMU), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA), BeyondSpring (BYSI), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP) and TG Therapeutics (TGTX).

Heron Therapeutics' management team includes the folowing people:

• Kevin C. Tang, Independent Chairman of the Board
• Robert Harvey Rosen, President, Director
• Barry D. Quart Pharm.D., Chief Executive Officer, Director
• Robert E. Hoffman, Chief Financial Officer, Senior Vice President - Finance, Principal Accounting Officer
• Kimberly J. Manhard, Executive Vice President - Drug Development
• David L. Szekeres, Senior Vice President, General Counsel, Business Development, Corporate Secretary
• Michael A. Adam Ph.D., Senior Vice President - Regulatory Affairs and Quality
• Thomas B. Ottoboni Ph.D., Senior Vice President - Pharmaceutical and Preclinical Research and Development
• Sean T. Ristine, Vice President - Human Resources
• Christian Waage, Director

Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (0.00%), Franklin Resources Inc. (0.00%), FMR LLC (0.00%), Janus Henderson Group PLC (0.00%), Vanguard Group Inc. (0.00%) and State Street Corp (0.00%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Heron Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., State Street Corp, Tang Capital Management LLC, Brandywine Global Investment Management LLC, California State Teachers Retirement System and Old West Investment Management LLC. View Insider Buying and Selling for Heron Therapeutics.

Heron Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Vanguard Group Inc., Rubric Capital Management LP, BlueCrest Capital Management Ltd, Royce & Associates LP, Northern Trust Corp, National Asset Management Inc. and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Heron Therapeutics.

Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Heron Therapeutics stock can currently be purchased for approximately $15.20.